A three‐way mixed ANOVA of normalized cortical thickness as a function of diagnosis (MD or control), MD onset (early or late), and ROI location (cPRL and cURL) was used to test the hypothesis that the PRL, which is used more in daily life than the cURL, will be thicker in the participants with central vision loss but not the controls. The gene discussed is PRL; the disease is Menkes disease.